Results from an international clinical trial show a significant reduction in risk of ventricular tachycardia (VT) recurrence, cardiovascular hospitalization, and death when catheter ablation is used as an early first-line treatment for patients with structural heart disease.
Results from a new clinical trial find human-oversight dependent continuous electrocardiography (ECG) monitors to more accurately detect significant arrhythmias than mobile cardiac telemetry (MCT).
A new study shows direct oral anticoagulants (DOACS) are more effective than aspirin (ASA) in reducing cerebrovascular events (CVE), including transient ischemic attack and stroke in patients undergoing ventricular tachycardia using radiofrequency catheter ablation (RFA).
The American College of Cardiology and Heart Rhythm Society, in collaboration with the Bristol Myers Squibb-Pfizer Alliance, are launching an innovative project to improve management of atrial fibrillation in underserved communities.
In response to the COVID-19 pandemic, the Heart Rhythm Society (HRS) led a global cross-sectional survey of more than 1,100 electrophysiologists (EPs) to better understand the prevalence of cardiac arrhythmias and treatment strategies in hospitalized COVID-19 patients.
A new clinical trial effectively uses pulsed field (PF) energy to treat patients with persistent or paroxysmal atrial fibrillation (AF) and showcases a novel approach to performing point-by-point ablation to provide safe and effective patient outcomes.
A new clinical study found that patients with atrial fibrillation (AF) experienced a high incidence of clinically silent brain infarcts, despite taking oral anticoagulants for stroke prevention. Silent brain infarcts were significantly associated with cognitive decline.
A new clinical trial is the first to compare the safety and efficacy of subcutaneous implantable cardioverter defibrillators (S-ICDs) to transvenous implantable cardioverter-defibrillators (TV-ICD).